*GMP (Good Manufacturing Practice) —rules that establish requirements for the organization of production and quality control of drugs for medical and veterinary use.
The Russian pharmaceutical company “Nanolek” was founded in 2011. It specializes in the production of import-substituting medicines for the prevention and treatment of socially significant diseases.
In 2020, the company was recognized as a backbone enterprise of the Russian economy. In 2021, “Nanolek” was included in RBC's rating — “50 Fastest Growing Companies in Russia”.
Company
“Nanolek” has accumulated a unique experience in technology transfer:
more than 10 innovative drugs have been localized at the plant in the Kirov region in partnership with big pharma companies — world industry leaders.
800
employees
23% of which are engaged solely in quality control
20
drugs
in the portfolio. 7 more drugs are under development
13.3
billion rubles
have been invested in the company since 2011
2.2
billion rubles
taxes paid to in the Kirov region over the past 5 years
NANOLEK IS A MEMBER OF ASSOCIATIONS
NANOLEK IS THE LEADER OF RATINGS
The mission
Protect people's lives and health by producing the world's best technologies, made available to everyone
Strategy
From the localization of the drugs of global pharmaceutical companies, to the biotech production of a full cycle and the development of innovative medicines “from scratch”
Partners
Our rule, without exception: All “Nanolek” partners are leaders in their field with impeccable reputations.
